BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210504
DTEND;VALUE=DATE:20210507
DTSTAMP:20260515T181259
CREATED:20210203T083221Z
LAST-MODIFIED:20210203T083221Z
UID:28753-1620086400-1620345599@www.pharmajournalist.com
SUMMARY:Multi-Functional Cell Therapies Summit
DESCRIPTION:Advance Cutting-Edge Research and Development with Next-Generation Cell Therapies\, to Deliver Best-in-Class Products to Patients in Need\nCell therapies hold life-saving potential for patients\, and the race is on to develop best-in-class\, living\, ‘thinking’ drugs. Relapse rates and barriers to solid tumor efficacy mean the cell therapy industry must innovate\, now more than ever.  \nThe inaugural Multi-Functional Cell Therapies Summit gathers the avantgarde to discuss strategies to weaponize cell therapies with antigenic\, engineered and combination approaches to create sophisticated\, multi-functional systems. \nFor more details about the program\, speaker faculty or pricing and discounts\, download the brochure.
URL:https://www.pharmajournalist.com/event/multi-functional-cell-therapies-summit/
LOCATION:EST | Digital
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210505
DTEND;VALUE=DATE:20210507
DTSTAMP:20260515T181259
CREATED:20210121T121615Z
LAST-MODIFIED:20210121T121835Z
UID:28605-1620172800-1620345599@www.pharmajournalist.com
SUMMARY:Chronic Hepatitis B Drug Development Summit
DESCRIPTION:The first ever meeting purpose-built for discussing the advancement of curative therapies for chronic HBV infection.  \nFeaturing an all-star speaker faculty from across industry\, NGOs and academia\, all dedicated to finding a curative therapy for Chronic HBV infection.  This is a unique opportunity to review the latest clinical investigations with novel and classic therapeutics including RNAi and immuno-therapies. \n \nHere is just a snapshot of some of the speakers who are joining us: \nYuchun Nie\, Senior scientist\, Aligos Therapeutics\nGaston Picchio\, Chief Development Officer\, Arbutus Biopharma\nWilliam Delaney\, Chief Scientific Officer\, Virology\, Assembly Biosciences (USA)\nStephane Daffis\, Scientist II\, Gilead Sciences\nPatricia Mendez\, Vice President – Clinical Development\, Immunocore Ltd\nAndrew Vaillant\, Chief Scientific Officer\, Replicor Inc.\nTom Evans\, Chief Scientific Officer\, Vaccitech\nDavid Anderson\, Chief Scientific Officer\, VBI Vaccines Inc. \nDon’t miss out on this opportunity to benchmark yourself against the competition\, get a comprehensive update on how the field stands and network with peers from across the field at the inaugural Chronic Hepatitis B Drug Development Summit.  Find out more >> https://ter.li/haruyt
URL:https://www.pharmajournalist.com/event/chronic-hepatitis-b-drug-development-summit/
LOCATION:Virtual Summit
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR